CyberKnife radiation in treatment of intermediate-risk prostate cancer

A new paper in the journal Radiation Oncology provides data on a series of 41 men treated with stereotactic body radiation therapy for intermediate-risk prostate cancer.

Ju et al. treated these 41 consecutive, intermediate-risk patients with 35 to 36.25 Gy in 5 fractions delivered using CyberKnife technology. All patients were assessed at baseline and followed-up for disease recurrence, PSA levels, toxicities, and quality of life (QOL).

Here are the results:

  • 41/41 patients (100 percent) completed treatment
  • The median follow-up was 21 months from treatment.
  • The average (mean) PSA level for the 41 patients was
    • 7.67 ng/ml before treatment
    • 0.64 ng/ml after treatment
  • 40/41 patients remained free from biochemical progression during the follow-up period
  • No patients exhibited Grade 3 or 4 toxicities.
  • Mean EPIC urinary irritation/obstruction and bowel QOL scores did decline post-treatment but subsequently returned to baseline.
  • No significant change in sexual QOL was observed.

The authors conclude that, in this group of patients, an adequate radiation dose was delivered to areas of expected, microscopic, extracapsular extension in the majority of patients. They further state that, in their opinion, “the short-term PSA response, biochemical relapse-free survival rate, and QOL in this interim analysis are comparable to results reported for prostate brachytherapy or external beam radiotherapy.”

Clearly, we still need data from larger, longer-term studies to know if CyberKnife therapy is as good or better than other forms of radiation therapy in men with intermediate-risk disease. However, the present study does, at least, give us some degree of insight into what might reasoably be expected.

2 Responses

  1. I thought the PSA level had to be over 10 to qualify for that designation?

  2. Peter:

    A man can have D’Amico intermediate-risk prostate cancer for any one of the following reasons: a PSA level between 10 and 20 ng/ml; a Gleason score of 7; a clinical stage of T2b.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: